Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Regulatory Briefs: Draft Guidances On Hearing Aids, Syphilis Tests; Upcoming Panel Meetings

This article was originally published in The Gray Sheet

Executive Summary

FDA issues draft guidance clarifying the difference between hearing aid devices and personal sound amplification products. Agency also issues draft guidance on the use of tests to screen human cells and tissues for syphilis. Boston Sci gets a new panel date for Watchman. More regulatory news.

You may also be interested in...

Industry, Consumers Seek Greater Clarity In Hearing Aid Draft Guidance

Companies and consumer groups asked FDA for a clearer distinction between hearing aid devices and personal sound amplification products in recent comments submitted in response to an FDA draft guidance.

Regulatory News In Brief

Agency issues proposed orders to reclassify intra-aortic balloon and control systems, tuberculosis IVDs and stair-climbing wheelchairs. Industry mainly supports FDA’s communications draft guidance. More regulatory news.

PROTECT AF Results Show Long-Term Efficacy Of Watchman LAA Closure Device

Boston Scientific is highlighting a secondary-endpoint analysis showing that the left-atrial appendage closure device reduced all-cause death by 34 percent. The company plans to submit a PMA for the device by the end of the second quarter.

Related Content


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts